[Asia Economy Reporter Hyungsoo Park] Mobis is soaring. It appears to be attracting attention as a beneficiary stock of the government's Green New Deal policy.
At 9:37 a.m. on the 29th, Mobis was trading at 2,945 won, up 20.04% from the previous trading day.
Mobis' business sectors are broadly classified into accelerators, nuclear fusion, and machine learning. Each sector forms a lineup of systems and equipment responsible for precision control functions. Among the main products, the accelerator control system and related equipment were supplied to the 4th generation synchrotron accelerator at the Pohang Accelerator Laboratory.
The nuclear fusion reactor control system is a core control system supplied to ITER (International Thermonuclear Experimental Reactor), which is currently being attempted for the first time in the world in France. Mobis is participating in building control systems for five out of six sectors.
Nuclear fusion power generation does not emit carbon dioxide or other greenhouse gases into the atmosphere and does not have nuclear waste problems like nuclear power generation. It does not require nuclear fission materials that could be misused for nuclear weapons, so phenomena such as reactor collapse that can occur in nuclear power plant accidents do not happen. It is being considered as an important alternative among future energy sources. Nuclear fusion, the energy source of the sun, is recognized as a future energy source capable of providing large-scale energy and environmentally friendly power generation.
On the 8th of last month, the government made a final decision to additionally construct a synchrotron accelerator in Cheongju, Chungbuk, with a project cost of over 1 trillion won. A synchrotron accelerator is a device that accelerates electrons to the speed of light and then bends them with magnets to generate synchrotron radiation. Synchrotron radiation is used in organic semiconductor device characteristic analysis for developing flexible or foldable displays, and in researching conductive plastic polymers for artificial muscles and joint development. Tamiflu, used as a treatment during the 2009 H1N1 flu pandemic, was developed using synchrotron radiation from the Stanford Linear Accelerator Center (SLAC) in the United States.
Using synchrotron accelerators, the structure and characteristics of disease proteins can be analyzed to develop new drugs that neutralize disease proteins. In the same context, research to reveal the structure of the novel coronavirus (COVID-19) is also being supported. Pohang PLS-II is also responding to the demands of domestic diagnostic reagent manufacturers. A cooperative system with specialized institutions researching COVID-19 treatments has also been established.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
